CREGANNA MEDICAL acquired by TE CONNECTIVITY
Context
The acquisition of the Irish medical specialist by the global connectivity leader represents a decisive step in the group's structural pivot toward high-margin, mission-critical sensing solutions. This transaction follows a clear industrial roadmap to reweight the portfolio toward applications in demanding environments. The strategic rationale for the move centers on the increasing complexity of minimally invasive surgery, where the integration of sensors and connectivity into delivery devices is becoming a primary technical requirement. By incorporating the target's specialized manufacturing expertise, the organization reinforces its ability to offer integrated, end-to-end clinical solutions for global medical device OEMs. The partnership is designed to leverage the acquirer's global scale and procurement resources to accelerate the international scaling of the target's product portfolio. This integration significantly expands the group's research and development capacity, providing the strategic depth required to navigate the high barriers to entry of the interventional medical market.
CREGANNA MEDICAL, which reported an EBITDA margin of in 2015, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Creganna Medical is a specialized technology organization dedicated to the design and manufacture of high-precision components for minimally invasive medical interventions. The entity’s business model is centered on the production of advanced delivery systems, including catheters and specialized access tubes, that facilitate clinical procedures in the cardiovascular and neurovascular fields. Its value proposition is anchored in material science expertise and technical operational depth, providing critical solutions for life-sustaining medical technologies. Strategically, the firm focuses on the industrialization of complex clinical devices that operate within the human circulatory system. By integrating sophisticated engineering and industrialized manufacturing, the organization facilitates surgical procedures with reduced patient trauma. The firm prioritizes technical innovation and regulatory compliance to address the increasing demand for outpatient and specialized interventional care.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2016 | CVC | DOC GENERICI | ITALY | Generics / Labs |
| 03/2016 | PSP INVESTMENTS | ANTELLIQ | FRANCE | Animal Health |
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs |
| 07/2015 | PERRIGO COMPANY | NATURWOHL PHARMA (YOKEBE) | GERMANY | Generics / Labs |
| 06/2015 | BC PARTNERS | PHARMATHEN | GREECE | CDMO |
| 06/2015 | WHITEWAVE | VEGA | CANADA | Nutrition & Dietary Supplements |
| 11/2014 | PERRIGO COMPANY | OMEGA PHARMA | BELGIUM | Generics / Labs |
| 11/2014 | QUALIUM | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2014 | INSTITUT MERIEUX / SAGARD / SOFIPROTEOL | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 03/2014 | MONTAGU PRIVATE EQUITY | Arkopharma | FRANCE | Nutrition & Dietary Supplements |
REFERENCES
Valuation range: EV 500M - 1.5b USD
Revenue range: 150M - 250M USD
EBITDA range: 50M - 100M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CREGANNA MEDICAL by TE CONNECTIVITY are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.